Results 1 to 10 of about 47,543 (305)

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma [PDF]

Technology in Cancer Research & Treatment, 2021
Purpose: Induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma.
Guoqiang Xu MD, Qiaoli Wang MD, Xingrao Wu MD, Chunyan Lv MD, Guilin Zeng MD, Zhihong Xue MD, Ruixue Cao MD, Nan Zhang BD, Wei Xiong PhD, Qin Huang MD   +9 more
doaj   +3 more sources

Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma [PDF]

International Journal of Radiation Oncology*Biology*Physics, 2008
Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy.A total of 45 patients (13 with proximal and 32 with ...
John W. Nelson, A. Paiman Ghafoori, Christopher G. Willett, Douglas S. Tyler, Theodore N. Pappas, Bryan M. Clary, Herbert I. Hurwitz, Johanna C. Bendell, Michael A. Morse, Robert Clough, Brian G. Czito   +10 more
openalex   +3 more sources

The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer [PDF]

World Journal of Surgical Oncology
Background This study aimed to compare the efficacy and toxicity of sequential chemoradiotherapy (SCRT) versus concurrent chemoradiotherapy (CCRT) in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer.
Yuhong Ma, Shujing Shi
doaj   +2 more sources

Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial [PDF]

BMC Cancer
Background The standard treatment for elderly patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy with S-1.
Ke Zhang, Qifeng Wang, Jianzhong Cao, Chengcheng Fan, Wenbin Shen, Qin Xiao, Xiaolin Ge, Tian Zhang, Xiao Liu, Xi Chen, Jie Dong, Zewei Li, Zhunhao Zheng, Cihui Yan, Ping Wang, Qingsong Pang, Wencheng Zhang   +16 more
doaj   +2 more sources

Bronchopleural Fistula After Concurrent Chemoradiotherapy [PDF]

Advances in Radiation Oncology, 2020
Jorien M. van de Pas, MD, Lori M. van Roozendaal, MD, PhD, Stofferinus L. Wanders, MD, Frank L. Custers, MD, Yvonne L.J. Vissers, MD, PhD, Erik R. de Loos, MD   +5 more
doaj   +3 more sources

Efficacy and prognosis of concurrent chemoradiotherapy in the management of recurrent cervical cancer: a retrospective study. [PDF]

Am J Transl Res
Yao D, Ding H, Wang W.
europepmc   +2 more sources

Outcome of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in non-metastatic locally advanced non-small cell lung cancer – A prospective and randomized study

Asian Journal of Medical Sciences, 2023
Background: Sequential chemoradiotherapy and concurrent chemoradiotherapy are two treatment options for locally advanced non-small cell lung cancer (NSCLC). Still there is limited data regarding which is the better treatment option.
Subir Pal , Anjan Bera , Soumen Mukherjee , Asmita Dasgupta , Srikrishna Mandal , Saptarshi Banerjee   +5 more
doaj   +1 more source

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial

JTO Clinical and Research Reports, 2022
Introduction: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC.
Hui Zhu, MD, Wenxiao Jia, PhD, Xuquan Jing, MD, Wei Huang, MD, Linlin Wang, MD, Jinming Yu, MD   +5 more
doaj   +1 more source

A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma

Radiation Medicine and Protection, 2022
Objective: To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate ...
Xin Dong, Wei Deng, Leilei Jiang, Dan Yang, Huiming Yu, Dongming Li, Anhui Shi, Rong Yu, Weihu Wang   +8 more
doaj   +1 more source

Survival and toxicity outcomes of induction chemotherapy followed by concurrent chemoradiotherapy compared with concurrent chemoradiotherapy alone in inoperable stage III and IVA/B head and neck cancer

Bangabandhu Sheikh Mujib Medical University Journal, 2022
Concurrent chemoradiotherapy with or without induction chemotherapy is widely practiced in inoperable stage III and IVA/B head and neck cancer. The aim of this study was to investigate the survival and toxicity outcomes of induction chemotherapy ...
Sajib Kumar Talukdhar, Sarwar Alam, Md Abdul Bari, Mohammad Jahan Shams, Md Sohidul Islam, Sadia Sharmin, Md Zillur Rahman Bhuiyan, Md Nazir Uddin Mollah   +7 more
doaj   +1 more source